THALIDOMIDE - RATIONALE FOR RENEWED USE IN IMMUNOLOGICAL DISORDERS

被引：52

作者：

SCHULER, U

EHNINGER, G

机构：

[1] Universitätsklinikum, ‘Carl Gustav Carus’, Medizinische Klinik I, Technische Universität Dresden, Dresden, 01307

来源：

DRUG SAFETY | 1995年 / 12卷 / 06期

关键词：

D O I：

10.2165/00002018-199512060-00002

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Despite its inherent teratog,oenic risk, thalidomide has over the years proven to be of clinical use in a small number of mainly immunological diseases (e.g. erythema nodosum leprosum, Behcet's syndrome and rheumatoid arthritis). The mode of action of thalidomide is still poorly understood. Recent research has shown a decrease in tumour necrosis factor-alpha (TNF alpha) during thalidomide treatment in several settings. Others have found altered expression of adhesion molecules. Currently, the most interesting new fields of application are the prevention and treatment of graft-versus-host disease in allogeneic bone marrow transplantation and the treatment of aphthous ulceration in HIV-positive patients. Contraceptive measures must be instituted in women receiving thalidomide, and careful monitoring for neurological adverse effects is required in all patients.

引用

页码：364 / 369

页数：6

共 60 条

[1]

Roath S., Elves M.W., Israels M.C.G., Effects of thalidomide and its derivatives on human leucocytes cultured in vitro, Lancet, 1, (1963)

[2]

Field E.O., Gibbs J.E., Tucker D.F., Et al., Effect of thalidomide on the graft versus host reaction, Nature, 211, (1966)

[3]

Sheskin J., Thalidomide in the treatment of lepra reactions, Clin Pharmacol Ther, 6, (1965)

[4]

Lehner T., Sullivan F.M., Thalidomide, orogenital ulcers, and the risk of teratogenesis, Lancet, 1, (1985)

[5]

Crawford C.L., Use of thalidomide in leprosy, BMJ, 302, (1991)

[6]

Jones G.R., Thalidomide: 35 years on and still deforming, Lancet, 343, (1994)

[7]

Hawkins D.F., Thalidomide for systemic lupus erythematosus, Lancet, 339, (1992)

[8]

Crawford C.L., Thalidomide neuropathy, N Engl J Med, 327, (1992)

[9]

Barnhill R.L., McDougall A.C., Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions, J Am Acad Dermatol, 7, (1982)

[10]

Stephens T.D., Proposed mechanisms of action in thalidomide embryopathy, Teratology, 38, (1988)

← 1 2 3 4 5 6 →